Comparison of cardiovascular disease risk assessment tools in primary prevention patients with raised lipoprotein(a)

被引:0
|
作者
Carlton, H. C. [1 ]
Banerjee, A. [2 ]
Burnett, D. [3 ]
Shipman, K. E. [4 ]
机构
[1] Univ Hosp Sussex NHS Trust, Dept Clin Chem, Chichester, England
[2] Univ Hosp Sussex NHS Trust, Dept Cardiol, Chichester, England
[3] Worthing Dist Hosp, Dept Cardiol, Worthing, England
[4] Brighton & Sussex Med Sch, Dept Med Educ, Brighton, England
关键词
D O I
10.1093/eurheartj/ehae666.2709
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:2
相关论文
共 50 条
  • [11] Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)-A review of the evidence
    Sukkari, Mohamad Hekmat
    Al-Bast, Basma
    Al Tamimi, Raad
    Giesing, William
    Siddique, Momin
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 15
  • [12] Comparison of Patients Classified as High-Risk between International Cardiovascular Disease Primary Prevention Guidelines
    Chapman, Niamh
    Breslin, Monique
    Zhou, Zhen
    Sharman, James E.
    Nelson, Mark R.
    Mcmanus, Richard J.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (15)
  • [13] Steno-Stiffness Approach for Cardiovascular Disease Risk Assessment in Primary Prevention
    Tomiyama, Hirofumi
    Ohkuma, Toshiaki
    Ninomiya, Toshiharu
    Mastumoto, Chisa
    Kario, Kazuomi
    Hoshide, Satoshi
    Kita, Yoshikuni
    Inoguchi, Toyoshi
    Maeda, Yasutaka
    Kohara, Katsuhiko
    Tabara, Yasuharu
    Nakamura, Motoyuki
    Ohkubo, Takayoshi
    Watada, Hirotaka
    Munakata, Masanori
    Ohishi, Mitsuru
    Ito, Norihisa
    Nakamura, Michinari
    Shoji, Tetsuo
    Vlachopoulos, Charalambos
    Aboyans, Victor
    Yamashina, Akira
    Yamashina, Akira
    Tomiyama, Hirofumi
    Ohishi, Mitusru
    Kario, Kazuomi
    Shoji, Testuo
    Ninomiya, Toshiharu
    Munakata, Masanori
    Watada, Hirotaka
    Tomiyama, Hirofumi
    Yamashina, Akira
    Nagano, Masahide
    Asayama, Kei
    Satoh, Michihiro
    Hirose, Takuo
    Utsugi, Megumi-Tsubota
    Kikuya, Masahiro
    Takashima, Naoyuki
    Chowdhury, Tanvir Turin
    Yukiyo, Ogata
    Kabutoya, Tomoyuki
    Mitsuki-Shinohara, Kayo
    Yamashita, Takeshi
    Matsumoto, Chisa
    HYPERTENSION, 2019, 73 (03) : 508 - 513
  • [14] Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review
    Brindle, P.
    Beswick, A.
    Fahey, T.
    Ebrahim, S.
    HEART, 2006, 92 (12) : 1752 - 1759
  • [15] Risk functions and the primary prevention of cardiovascular disease
    Grau, Maria
    Marrugat, Jaume
    REVISTA ESPANOLA DE CARDIOLOGIA, 2008, 61 (04): : 404 - 416
  • [16] Risk scoring for the primary prevention of cardiovascular disease
    Karmali, Kunal N.
    Persell, Stephen D.
    Perel, Pablo
    Lloyd-Jones, Donald M.
    Berendsen, Mark A.
    Huffman, Mark D.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (03):
  • [17] Biomarkers and Cardiovascular Risk Assessment for Primary Prevention: An Update
    Gilstrap, Lauren G.
    Wang, Thomas J.
    CLINICAL CHEMISTRY, 2012, 58 (01) : 72 - 82
  • [18] Biomarkers and cardiovascular risk assessment for primary prevention: an update
    Gilstrap, Lauren G.
    Wang, Thomas J.
    BIOCHIMICA CLINICA, 2013, 37 (01) : 53 - 63
  • [19] Association of Lp(a) (Lipoprotein[a]) and Hypertension in Primary Prevention of Cardiovascular Disease: The MESA
    Rikhi, Rishi
    Bhatia, Harpreet S.
    Schaich, Christopher L.
    Ashburn, Nicklaus
    Tsai, Michael Y.
    Michos, Erin D.
    Chevli, Parag A.
    Herrington, David M.
    Tsimikas, Sotirios
    Shapiro, Michael D.
    HYPERTENSION, 2023, 80 (02) : 352 - 360
  • [20] ASSESSMENT OF CARDIOVASCULAR RISK AND STATIN UTILIZATION FOR PRIMARY PREVENTION IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Patel, Pragnesh J.
    Patil, Rashmee
    Tansel, Aylin
    Dhingra, Sadhna
    Sood, Gagan K.
    GASTROENTEROLOGY, 2017, 152 (05) : S1203 - S1204